The DOI matches its Crossref record; 110 of the 112 references it cites were found in a registry or an index; none of the 72 sources its claims cite is checked for support yet.
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Open accessAbstract
Conservative surgical treatment for symptomatic endometriosis is frequently associated with only partial relief of pelvic pain or its recurrence. Therefore, medical therapy constitutes an important alternative or complement to surgery. However, no available compound is cytoreductive, and suppression instead of elimination of implants is the only realistic objective of pharmacological intervention. Because this implies prolonged periods of treatments, only medications with a favourable safety/tolerability/efficacy/cost profile should be chosen. In the past few years, innumerable new drugs for endometriosis, which would interfere with several hypothesized pathogenic mechanisms, have been studied and their use foreseen. However, robust evidence of in vivo safety and efficacy is lacking and, at the moment, the principal modality to interfere with endometriosis metabolism is still hormonal manipulation. Regrettably, in spite of consistent demonstration of a major effect on pain even in patients with deeply infiltrating lesions, progestins are underestimated and dismissed in favour of more scientifically fashionable and up-to-the-minute alternatives. Moreover, oral contraceptives (OCs) dramatically reduce the rate of post-operative endometrioma recurrence and should now be considered an essential part of long-term therapeutic strategies in order to limit further damage to future fertility. Finally, women who have used OC for prolonged periods will be protected from an increased risk of endometriosis-associated ovarian cancer. To avoid the several subtle modalities for distorting facts and orientating opinions in favour of specific compounds, progestins and monophasic OC used continuously are here proposed as the reference comparator in all future randomized controlled trials on medical treatment for endometriosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that medical treatment for endometriosis should aim at long-term suppression rather than cure, and that progestins and continuous monophasic oral contraceptives (OCs) are effective, safe, inexpensive options that are underused. It proposes these as reference comparators in future randomized controlled trials and highlights postoperative OC use for preventing endometrioma and symptom recurrence.
Key findings
- No available drug is cytoreductive; suppression is the only realistic objective, so prolonged therapy is needed. In nine controlled trials identified from 1990–2010, progestins and OCs relieved pain and were generally not inferior to danazol, GnRH agonists, and aromatase inhibitors.
- Postoperative OC use dramatically reduced endometrioma recurrence in three controlled studies, with odds ratios from 0.04 (Takamura et al., 2009) to 0.32 (Seracchioli et al., 2010a). Two RCTs showed reduced dysmenorrhoea recurrence with postoperative progestin/OC versus expectant management (OR 0.14 and 0.32).
- Recurrence after conservative surgery is common: 10% at 1 year, 25% at 3 years, and 45% at 5 years (Evers et al., 1991); >20% at 2 years and 40–50% at 5 years (Guo, 2009); endometrioma recurrence reportedly 30–50% after 2–5 years.
- Costs are substantial: global endometriosis cost was $18.8–$22 billion per year based on 2002 US data; annual therapy costs ranged from €18 for low-dose norethisterone acetate to about €2100 for aromatase inhibitors or GnRH agonists, and about €4200 if combined.
Methods
- Narrative review/opinion article; no primary data. A MEDLINE search from January 1990 to July 2010 in English (MeSH terms: endometriosis, progestins, OCs, medical therapy) identified nine controlled trials comparing a progestin or OC with an alternative hormonal compound.
- A second MEDLINE search from January 2000 to July 2010 (MeSH terms: endometriosis, endometrioma, recurrence, OC, laparoscopy) identified three controlled studies on long-term postoperative OC use and endometrioma recurrence.
- The paper also cites RCTs on postoperative progestin/OC use for symptom recurrence; study quality was not assessed, and no meta-analysis was performed.
Limitations
- Stated: study quality was not assessed in the MEDLINE search; information on the cost of endometriosis to patients and society is limited.
- Evident: this is a narrative/opinion review with explicit advocacy for progestins and OCs, without systematic quality appraisal, risk-of-bias assessment, or meta-analysis; conclusions may be influenced by selected citation and interpretation of the literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
49 Not checked yet · 33 Own interpretation · 6 No basis given · 1 Own method
In the paper
“women who have used OC for prolonged periods will be protected from an increased risk of endometriosis-associated ovarian cancer”
- Also stated in: § Life is now! · hedged
“women who have used OC for prolonged periods might be reassured that they will be protected from an increase in risk of endometriosis-associated ovarian cancer (Missmer et al., 2004)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
What the sources say
- Not checked yetcites Missmer et al., 2004 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Life is now! · hedged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“in spite of consistent demonstration of a major effect on pain even in patients with deeply infiltrating lesions, progestins are underestimated and dismissed in favour of more scientifically fashionable and up-to-the-minute alternatives”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, robust evidence of in vivo safety and efficacy is lacking and, at the moment, the principal modality to interfere with endometriosis metabolism is still hormonal manipulation.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“oral contraceptives (OCs) dramatically reduce the rate of post-operative endometrioma recurrence”
- Also stated in: § Prevention of recurrence? Yes we can! · boosted
“A dramatic reduction in the risk of reappearance of endometriotic cysts in OC users was consistently observed independent of cyclic or continuous use, with odds ratios varying from 0.04 (Takamura et al., 2009) to 0.32 (Seracchioli et al., 2010a).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
What the sources say
- Not checked yetcites Takamura et al., 2009
- Not checked yetcites Seracchioli et al., 2010a
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Prevention of recurrence? Yes we can! · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“A decreased PR-B/PR-A ratio has been demonstrated not only in ectopic tissue (Attia et al., 2000), but also in eutopic endometrium of women with endometriosis (Igarashi et al., 2005), albeit not consistently (Bukulmez et al., 2008).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Challenging conventional biologic wisdom
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“the induction of experimental disease in mice leads to a completely opposite hormonal receptor expression, as total endometrial PR and PR-B were shown to be increased, and PR-A decreased in animals with endometriosis”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Challenging conventional biologic wisdom
What the sources say
- Not checked yetcites Lee et al., 2009
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Numerous clinical studies and systematic reviews have consistently demonstrated that hormonal compounds with very dissimilar pharmacological profiles determine comparable pelvic pain reduction.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites American College of Obstetricians and Gynecologysts, 2000
- Not checked yetcites Kennedy et al., 2005
- Not checked yetcites Royal College of Obstetricians and Gynaecologysts, 2006
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“and, most importantly, with potentially severe side effects”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“several of the compounds included in Table I are associated with uncertain or no efficacy, such as pentoxifylline (Lv et al., 2009) or anti-TNF-a (Lv et al., 2010)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites Lv et al., 2009
- Not checked yetcites Lv et al., 2010
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Almost all of the completed clinical trials for which no information on their outcome is available in the public domain were sponsored by pharmaceutical companies.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Introduction
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- Probably not a substantial claim. 13
- The quote only partly states this claim. 1
- It may state two separate claims as one. 14
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, no available compound is cytoreductive, and suppression instead of elimination of implants is the only realistic objective of pharmacological intervention.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“generally well-tolerated”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
In the paper
“After treatment discontinuation, symptoms recurred without significant between-group differences, demonstrating that also aromatase inhibitors are neither cytoreductive nor curative.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
What the sources say
- Not checked yetcites Ferrero et al., 2009b
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Disease control may result in an acceptable improvement of quality of life, only if also safety, tolerability and costs of medications are taken into adequate account.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of major untoward effects may be acceptable in the above clinical context, but not in otherwise healthy women affected by a benign condition.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there are also substantial economic implications if efficacy is overestimated and the medication over-utilized, given that usually new molecules are among the most costly drugs on the market”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: New molecules are usually among the most costly drugs on the market.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, again it is unclear if the increased expression of this cytochrome P-450 complex constitutes the very reason for survival and proliferation of regurgitated endometrial cells, or if it is the consequence of local inflammation”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moreover, during the reproductive period, aromatase inhibitors stimulate ovarian function, as they reduce the hypothalamic-pituitary estrogen feedback, with consequent rise in GnRH secretion, elevations in FSH and LH, and augmented follicular development.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“for the present the therapeutic target is not endometriosis cytoreduction, but suppression, which implies the survival of ectopic implants independently of the drug type, dosage, and duration of use (Evers, 1987)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites Evers, 1987 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: A compound with selective properties only against the ectopic endometrial cell has not yet been synthesized.
In the paper
“According to Evers et al. (1991), 10% of patients redeveloped signs and symptoms of endometriosis after a 1-year follow-up period, 25% after 3 years and 45% after 5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites Evers et al., 1991
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In both cases, subjective and metabolic untoward effects would considerably undermine safety and tolerability.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Study quality was not assessed.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In fact, prescribing medications for a few months has no clear rationale and exposes women to extenuating recurrences of symptoms and lesions and to the risk of repetitive surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maintaining that progestins and OCs may be of a little value in the prevention of endometrioma recurrence and that the use of post-operative medications may cause unnecessary side effects and cost increase seems questionable in light of recent research findings.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“which is substantially higher than the estimated costs of other chronic disorders, such as Crohn's disease ($865 million) and migraine ($13-17 billion; Rogers et al., 2009).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
What the sources say
- Not checked yetcites Rogers et al., 2009
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these medications are still addressed with scepticism and sometimes not even mentioned among effective therapeutic alternatives.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“Also DeCherney (1992) maintains that the endometriosis annual recurrence rate may be as high as 15% and that cumulative rates 40% after 3-5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites DeCherney, 1992
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“According to studies based on 2002 US data, the global cost of the disease (including analgesics, hormonal therapies, gynaecological consultations, hospital admissions, surgical procedures, days off-work and reduced productivity) varies between $18.8 and $22 billion per year (Gao et al., 2006;Simoens et al., 2007)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, pain symptoms relapse exposes patients to repetitive suffering, frustration, multiple courses of medical therapy and risk of serial surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recently, Guo (2009) calculated that the disease relapse rate is higher than 20% at 2 years and 40 -50% at 5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites Guo, 2009
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The latest pills are generally the most expensive, but not necessarily the most cost-effective.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Not all women using progestins will be relieved from pain, not all will be satisfied with their treatment, not all will continue it and not all will avoid surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“as the mechanism of action seems to be ovulation inhibition.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“should be informed in an unbiased manner, as any misinformation may expose many of them to repeated surgery and a decrease in the probability of conception.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“But at least two-thirds of them could substantially ameliorate their health-related quality of life, controlling the disease with marginal associated morbidity.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
The paper relies on this without support.
Definitive surgery for endometriosis is generally not accepted by patients wishing to preserve fertility.
“an option generally not accepted by patients wishing to preserve fertility”
The paper relies on this without support.
Publication of reports in peer-reviewed journals is the most important source of information on novel drugs for physicians who generally have limited clinical experience with the latest treatments.
“publication of reports in 'peer-reviewed' journals constitutes the most important source of information on novel drugs for physicians who generally have limited clinical experience with the latest treatments”
The paper relies on this without support.
New molecules are usually among the most costly drugs on the market.
“usually new molecules are among the most costly drugs on the market”
The paper relies on this without support.
A compound with selective properties only against the ectopic endometrial cell has not yet been synthesized.
“As a compound with selective properties only against the ectopic endometrial cell has not yet been synthesized”
The paper relies on this without support.
Medical therapies for endometriosis are not curative.
“given that medical therapies for endometriosis are not curative”
The paper relies on this without support.
Medical treatment for endometriosis does not influence reproductive performance of infertile women.
“Medical treatment for endometriosis does not influence reproductive performance of infertile women.”
The paper relies on this without support.
Dropouts are usually largely dissatisfied because of persisting pain or development of major side effects.
“In fact, dropouts are usually largely dissatisfied because of persisting pain or development of major side effects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, when hormonal treatments are to be continued for long periods, estrogen-progestins and progestins appear to be among the compounds that most favorably balance benefits, harms, and costs (30,31).”
From A stepped-care approach to symptomatic endometriosis management: A participatory research initiative (2018) · cites this paper as [31]
Citations
Cites
1 retracted
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Prentice, A., Deary, A., Goldbeck-Wood, S., Farquhar, C., & Smith, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000346 · Cited by 116 · cited 1×
“…in relieving pain, generally well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et…”
BackgroundRetractedGiudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924 · cited 1×
“Endometriosis is an estrogen-dependent chronic inflammatory disease (Giudice, 2010) that can be effectively cured by definitive surgery (Shakiba et al., 2008), an option generally not accepted by patients wishing to preserve fertility.”
BackgroundBulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 2×
“This is acknowledged in several guidelines on the treatment of endometriosis (American College of Obstetricians and Gynecologysts, 2000; Kennedy et al., 2005; Royal College of Obstetricians and Gynaecologysts, 2006; Practice Committee of the American Society for Reproductive Medicine, 2008; Society of Obstetricians an…”
BackgroundMethodRecurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719 · cited 3×
“This would explain why 9% of patients do not respond to progestin treatment (Guo, 2009). by guest on Septem ber 24, 2015 http://hum rep.oxfordjournals.org/ D ow nloaded from The expression of human progesterone receptor (PR) is controlled by two promoters that direct the synthesis of mRNA…”
BackgroundStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 2×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et al., 2010a).”
BackgroundPetta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363 · cited 1×
“…not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al.,…”
BackgroundEndometriosis: cost estimates and methodological perspective
Simoens, S., Hummelshoj, L., & D'Hooghe, T. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm010 · Cited by 357 · cited 2×
“8 and $22 billion per year (Gao et al., 2006; Simoens et al., 2007), which is substantially higher than the estimated costs of other chronic disorders,”
BackgroundInfluentialPriorities for Endometriosis Research: Recommendations From an International Consensus Workshop
Rogers, P. A. W., D’Hooghe, T. M., Fazleabas, A., Gargett, C. E., Giudice, L. C., Montgomery, G. W., Rombauts, L., Salamonsen, L. A., & Zondervan, K. T. (2009) · Reproductive Sciences · doi:10.1177/1933719108330568 · Cited by 346
Surgical Treatment of Endometriosis: A 7-Year Follow-up on the Requirement for Further Surgery
Shakiba, K., Bena, J. F., McGill, K. M., Minger, J., & Falcone, T. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181758ec6 · Cited by 339 · cited 3×
“(Giudice, 2010) that can be effectively cured by definitive surgery (Shakiba et al., 2008), an option generally not accepted by patients wishing to preserve fertility.”
Background
Research works printed but not linked: 18
- 2006, Cochrane database of systematic reviews (Online), 18, CD005072
- 2005, Fertility and sterility, 81, 290
- 2008, MIDDLE EAST FERTIL SOC J, 13, 304
- 2009, Cochrane database of systematic reviews (Online), 15, CD004753
- 2008, 11, 1533
- 2007, Cochrane database of systematic reviews (Online), 18, CD001019
- 1991, The British journal of clinical practice, 45, 45
- 2009, Cochrane database of systematic reviews (Online), 8, CD007677
- 2010, Cochrane database of systematic reviews (Online), 17, CD008088
- 2003, Journal of Molecular Endocrinology, 2, 241
- 2008, Fertility and sterility, 90, S260
- 2000, Cochrane database of systematic reviews (Online), 2, CD002122
- 2004, Cochrane database of systematic reviews (Online), 2, CD000346
- 2008, 11, 1561
- 2007, Cochrane database of systematic reviews (Online), 17, CD000068
- 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obst trique et gyn cologie du Canada : JOGC, 32, S1
- 2008, American journal of obstetrics and gynecology, 198, 504
- 2004, Cochrane database of systematic reviews (Online), 3, CD003678
Cited by
Sorted by citations
Items 101–181 of 181
Mendoza, N., Lobo, P., Lertxundi, R., Correa, M., Gonzalez, E., Salamanca, A., & Sánchez‐Borrego, R. (2014) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2014.927423 · Cited by 17
Challenges in the development of novel therapeutic strategies for treatment of endometriosis
Vanhie, A., Tomassetti, C., Peeraer, K., Meuleman, C., & D’Hooghe, T. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1118461 · Cited by 17
Ghosh, D., Filaretova, L. P., Bharti, J., Roy, K. K., Sharma, J. B., & Sengupta, J. (2020) · Reproductive Medicine · doi:10.3390/reprodmed1010004 · Cited by 18
Scala, C., Maggiore, U. L. R., Barra, F., Venturini, P. L., & Ferrero, S. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.01.022 · Cited by 18
Hogg, S., & Vyas, S. K. (2015) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2015.02.001 · Cited by 17
A pilot study on the use of andrographolide to treat symptomatic adenomyosis
Liu, X., Yu, S., & Guo, S. (2014) · Gynecology and Minimally Invasive Therapy · doi:10.1016/j.gmit.2014.12.002 · Cited by 16
Lete, I., Häusler, G., Pintiaux, A., Jamin, C., Nappi, R. E., Fiala, C., Chabbert‐Buffet, N., & Lobo, P. (2017) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2017.1400001 · Cited by 12
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
Dicitore, A., Castiglioni, S., Saronni, D., Gentilini, D., Borghi, M. O., Stabile, S., Vignali, M., Blasio, A. M. D., Persani, L., & Vitale, G. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.10.004 · Cited by 13
Vercellini, P., Ottolini, F. L., Frattaruolo, M. P., Buggio, L., Roberto, A., & Somigliana, E. (2018) · Reproductive Sciences · doi:10.1177/1933719117749759 · Cited by 14
Self-citationWestern Herbal Medicine, Epigenetics, and Endometriosis
Stephens, L., Whitehouse, J. M., & Polley, M. J. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.0623 · Cited by 14
Badie, A., Saliminejad, K., Salahshourifar, I., & Khorshid, H. R. K. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1631790 · Cited by 12
“The primary symptom of endometriosis, pelvic pain, is also found to be relieved by the use of anti-inflammatory drugs [10].”
BackgroundLermann, J. H., Topal, N., Renner, S. P., Beckmann, M. W., Burghaus, S., Adler, W., & Heindl, F. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.05.007 · Cited by 12
“Drug treatment is one alternative [8].”
Forno, S. D., Solfrini, S., Ferrini, G., Zannoni, L., Bertoldo, V., Monti, G., Leonardi, D., Labate, A. M. M., Paccapelo, A., & Seracchioli, R. (2013) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000167 · Cited by 9
“hormone (GnRH) analogues in terms of pain relief with lower side effects for long-term assumption (15-18).”
BackgroundClinical Aspects of Adolescent Endometriosis
Nakamura, T. (2021) · Endocrines · doi:10.3390/endocrines2030028 · Cited by 12
“Although the role of post-operative long-term medical therapy in suppressing endometriosis recurrence is clearly demonstrated in adults, its role is yet unclear in adolescents [11,14,59].”
BackgroundHistone deacetylase inhibitors as therapeutics for endometriosis
Li, X., Liu, X., & Guo, S. (2012) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.52 · Cited by 11
Mandai, M., Suzuki, A., Matsumura, N., Baba, T., Yamaguchi, K. D., Hamanishi, J., Yoshioka, Y., Kosaka, K., & Konishi, I. (2012) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-011-0002-3 · Cited by 10
An overview of early drug development for endometriosis
Maggiore, U. L. R., & Ferrero, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1126579 · Cited by 10
The impact of IVF on deep invasive endometriosis
Berlanda, N., Benaglia, L., Bottelli, L., Torri, C., Busnelli, A., Somigliana, E., & Vercellini, P. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology X · doi:10.1016/j.eurox.2019.100073 · Cited by 10
“5–5% at 3–6 months) that was halved considering that a consistent proportion of women (about half in our population) was assuming hormonal therapies, a treatment that is known to markedly reduce the risk of recurrences [20].”
BackgroundSelf-citationRectosigmoid endometriosis: Diagnostic pitfalls and management – A case report
Piachas, A., Smyrnis, P., & Tooulias, A. I. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5222 · Cited by 9
I405V polymorphism ofCETPgene and lipid profile in women with endometriosis
Sahmani, M., Ghaleh, T. D., Darabi, M., Darabi, M., Rashvand, Z., & Najafipour, R. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.797396 · Cited by 9
“Despite extensive research, the definitive cause of endometriosis is still unknown [5,6].”
BackgroundAdamyan, L. V., Pivazyan, L. G., Mailova, K. S., Peshkova, I. O., & Stepanian, A. A. (2024) · Russian Journal of Human Reproduction · doi:10.17116/repro20243006161 · Cited by 8
Khan, K. N., de Ziegler, D., & Guo, S. (2024) · Human Reproduction · doi:10.1093/humrep/deae006 · Cited by 7
Nuclear expression of VDR and AHR is mutually exclusive in glandular cells in endometriosis
Pascali, F. D., Casarini, L., Kühn, C., Simoni, M., Mahner, S., Jeschke, U., & von Schönfeldt, V. (2021) · Histochemistry and Cell Biology · doi:10.1007/s00418-021-02005-9 · Cited by 10
Keep the pressure on for more transparency of clinical trials on endometriosis
Guo, S. (2013) · Gynecology and Minimally Invasive Therapy · doi:10.1016/j.gmit.2013.05.007 · Cited by 8
The Epigenetics of Endometriosis
Guo, S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-388415-2.00022-6 · Cited by 8
Surgical management of endometriosis to optimize fertility
Hamilton, K. M., VanHise, K., Truong, M., Wright, K. N., & Siedhoff, M. T. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000876 · Cited by 9
“Initial studies did not show a similar benefit of medical therapy alone for spontaneous pregnancy, but more recent investigations demonstrate value for gonadotropin-releasing hormone (GnRH) agonists [32,33].”
ResultCanis, M. J., & Guo, S. (2023) · Human Reproduction · doi:10.1093/humrep/dead061 · Cited by 8
‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis
SHULMAN, L. P. (2011) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2011.05.080 · Cited by 7
Vercellini, P., Ottolini, F. L., Frattaruolo, M. P., Buggio, L., Roberto, A., & Somigliana, E. (2018) · Gynecologic and Obstetric Investigation · doi:10.1159/000486335 · Cited by 8
Self-citationComparing treatments for endometriosis-related pain symptoms in patients with migraine without aura
Morotti, M., Remorgida, V., Buccelli, E., Venturini, P. L., & Ferrero, S. (2012) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.12.38 · Cited by 7
Atlıhan, U., Yavuz, O., Ata, C., Avşar, H. A., & Erkılınç, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1581661 · Cited by 5
RNA-lipid nanoparticle therapeutics for women’s health
Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 7
The Place of Gonadotropin-Releasing Hormone Agonists in the Management of Endometriosis
Descamps, P., En, A., Leng, J., Salehpour, S., & Chapron, C. (2014) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000174 · Cited by 4
Giannini, A., Palla, G., Goglia, L., Genazzani, A. R., Genazzani, A. D., & Simoncini, T. (2015) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000215 · Cited by 5
“Any supportive strategy resulting in a potentiation of this antiinflammatory action would thus add to the available therapeutic strategies, and may even be critical in patients with contraindications to medical or surgical approaches (16, 17, 19).”
BackgroundInvolvement of Prostaglandins in the Pathophysiology of Endometriosis
Gabriela, F., & Carla, N. (2012) · InTech eBooks · doi:10.5772/30414 · Cited by 5
Effect of Long-Term Use of Hormones on Endometriomas
Berlanda, N., Morini, M., Dridi, D., Braud, L. V. D., Bracco, B., & Vercellini, P. (2013) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-013-0053-8 · Cited by 4
Self-citationOral contraceptives and endometriosis
Roman, H. (2011) · Human Reproduction · doi:10.1093/humrep/der085 · Cited by 5
Mooney, S. S., & Grover, S. R. (2021) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13289 · Cited by 5
Non-contraceptive benefits of oral contraceptives
Dhont, M. A. (2011) · Open Access Journal of Contraception · doi:10.2147/oajc.s14246 · Cited by 4
Viganò, P., Rabellotti, E., Pagliardini, L., Somigliana, E., Candiani, M., & Vercellini, P. (2012) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-012-0013-8 · Cited by 4
“leukocyte activation such as interleukin-2 receptor gamma (IL-2RG), were shown to be differentially expressed in blood leukocytes of women with endometriosis compared to those present in control women [13]. Finally, based on population-based epidemiological studies, women with endometriosis have an increased risk for…”
InfluentialSelf-citationRodrigues, R. C., Belham, F. S., Garcia, A., Satler, C. E., Tomaz, C. A. B., & Tavares, M. C. H. (2019) · International Journal of Endocrinology · doi:10.1155/2019/2047803 · Cited by 4
“These contraceptives are also widely used for the treatment of clinical conditions such as endometriosis, polycystic ovary, premenstrual syndrome, heavy menstrual bleeding, and menstrual cramps [2, 3].”
BackgroundMedikamentöse Behandlung der Endometriose
Janschek, E., Wölfler, M. M., Zeppernick, M. M., & Meinhold-Heerlein, I. M. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04663-7 · Cited by 4
Hormonal anticonception anno 2013: a clinician's view.
Dhont, M. A., & Verhaeghe, V. (2013) · Europe PMC (PubMed Central) · Cited by 3
Triantafyllidou, O., Kolovos, G. N., Voros, C., Vlachos, A., Vakas, P., & Vlahos, N. (2020) · Human Fertility · doi:10.1080/14647273.2019.1704451 · Cited by 3
“These drugs have a favourable safety, tolerability, efficacy and cost profile, which permits administration for prolonged periods (months or even years) (Vercellini et al., 2011).”
BackgroundPrise en charge des endométriomes
Chauvet, P., Roman, H., Grémeau, A., Canis, M. J., & Bourdel, N. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.10.004 · Cited by 3
Safety and efficacy of hormonal therapies used to treat endometriosis in women suffering migraine
Perrone, U., Barra, F., Evangelisti, G., Izzotti, A., Gustavino, C., Antonelli, A., Maggiore, U. L. R., & Ferrero, S. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2627190 · Cited by 2
Medical management of endometriosis
Black, K. I., & Fraser, I. S. (2012) · Australian Prescriber · doi:10.18773/austprescr.2012.050 · Cited by 2
Олеговна, Д. С., Berlim, Y. D., Станиславович, Г. В., Викторовна, К. Л., & Arechan, K. A. (2015) · Russian Journal of Human Reproduction · doi:10.17116/repro201521398-105 · Cited by 2
FACULTE MIXTE DE MEDECINE ET DE PHARMACIE DE ROUEN
Eltchaninoff, H., Lacroix, D., & Savoure, D. A. (2013) · Cited by 2
Adamyan, L. V., Gardanova, Z. R., Львовна, Я. Е., Ovakimyan, A. S., & Kozachenko, I. F. (2016) · Russian Journal of Human Reproduction · doi:10.17116/repro201622285-93 · Cited by 2
Matak, L., Bačić, I., Mihanović, J., et al. (2019) · Case Reports in Perinatal Medicine · doi:10.1515/crpm-2019-0028 · Cited by 2
“Pharmacological treatments are symptomatic and not cytoreductive: lesions survive any drug, at any dose, for any period of use, ready to resume their metabolic activity once treatment is discontinued [16].”
BackgroundROLE OF STROMAL CELL-DERIVED FACTOR-1 IN NEOANGIOGENESIS IN ENDOMETRIOSIS LESIONS
Virani, S. (2011) · QSpace (Queen's University Library) · Cited by 2
Morotti, M., Buccelli, E., Venturini, P. L., Remorgida, V., & Ferrero, S. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60905-9 · Cited by 2
“Patients invited to participate into the study were informed that medical treatments are effective in relieving pain symptoms caused by endometriosis but they are not curative, and that pain symptoms often recur to a degree similar to baseline when the treatments are discontinued [19].”
BackgroundFrom endometriosis to perineal trauma
Geirsson, R. T. (2013) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12058 · Cited by 1
Progestins in the Medical Management of Endometriosis
Singh, P., & Batra, S. (2017) · Journal of medical research/The journal of medical research · Cited by 1
ENDOMETRİOZİS AĞRI YÖNETİMİNDE GÜNCEL TEDAVİ YAKLAŞIMLARI VE HEMŞİRENİN ROLÜ
BİNGÖL, D., & Duman, N. B. (2021) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.681860 · Cited by 1
Cirugía de la endometriosis anexial
Chauvet, P., Grémeau, A.-S., Roman, H., Canis, M. J., Rabischong, B., Pouly, J.-L., & Bourdel, N. (2017) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(17)84286-7 · Cited by 1
Bukar, A., Waziri, G., Buhari, M. A., et al. (2025) · Haematology Journal of Bangladesh · doi:10.37545/haematoljbd2025152 · Cited by 1
Medical and Surgical Management of Endometriosis
Zupi, E., Lazzeri, L., & Exacoustós, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-71138-6_2 · Cited by 1
Hormonal Therapy in Endometriosis and Adenomyosis: Oral Contraceptives
Komatsu, H., Taniguchi, F., & Harada, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-97236-3_40 · Cited by 1
Luo, M., Cai, X., Liu, X., Yan, D., & Guo, S. (2022) · Medical Research Archives · doi:10.18103/mra.v10i11.3341 · Cited by 1
Molecular Mechanisms Underlying Endometriosis and Endometriosis‐Related Cancers
Dinulescu, D. M. (2011) · Wiley eBooks · doi:10.1002/9781444398519.ch50 · Cited by 2
Cirugía de la endometriosis anexial
Roman, H., Bourdel, N., Opris, I., Tarta, O., Pușcașiu, L., Auber, M., & Marpeau, L. (2010) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(10)70773-6
Reply: Oral contraceptives and the endometriosis domino effect
Vercellini, P., Crosignani, P. G., Somigliana, E., Viganò, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/der087
Self-citationEffect of DMPA on IL-1 Alpha in Serum of Women with Endometrioma
Lupthaluk, W., Weerakiet, S., Leelaphiwat, S., Rattanasiri, S., & Sukprasert, M. (2013) · Thai Journal of Obstetrics and Gynaecology
Olivares, C. N. (2012) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
The experience of Visanne use in patients of reproductive age with external genital endometriosis
Kolesnikova, L. V., Ermolova, N. V., Анатольевич, Л. В., Маркарьян, И. В., & Avanesova, T. G. (2016) · Russian Journal of Human Reproduction · doi:10.17116/repro2016223101-106
DESOGESTREL IN THE PREOPERATIVE TREATMENT OF ENDOMETRIOTIC CYSTS
Matasariu, D. R., Iacob, M., Dumitraşcu, I., et al. (2015) · The Medical-Surgical Journal
Консенсус по ведению эндометриоза
Johnson, N. P., & Hummelshøj, L. (2013) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2013.12.66-88
Pharmacological Treatment of Chronic Pelvic Pain
Shetty, A., Morice, O., & Elneil, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-40862-6_76
Mueller, M., & der Endometriose, T. (2016)
Goetsch, A. L., Kimelman, D., & Woodruff, T. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-52316-3_12
Zhang, Y., Zhu, Y., & Sun, J. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s377418
“Given that the efficacy of COCs and progestins have been widely acknowledged, they are suggested to be the reference comparator for randomized controlled trials on new endometriosis drugs.(6) As suppressive solutions to endometriosis, COCs and progestins have similar efficacy in relieving pain and other symptoms,(5) l…”
BackgroundMorsi, A. A., Ahmad, N., & Amer, W. M. (2023) · Evidence Based Women s Health Journal · doi:10.21608/ebwhj.2023.196654.1237
Atwa, K. A., Ibrahim, Z. M., Bassuony, E. M. E., Taha, O. T., & Elgedawy, A. M. (2023) · The Egyptian Journal of Fertility of Sterility · doi:10.21608/egyfs.2023.320851
Awar, S. A. A. R. A., & Zaręba, K. T. (2024) · Gulf Education and Social Policy Review (GESPR) · doi:10.18502/gespr.v4i2.15136
A Rare Case of the Bladder Endometriosis and Overview of the Literature
Mert, Ş. A., Dilbaz, B., Ergani, S. Y., et al. (2024) · Medical Research Reports · doi:10.55517/mrr.1466301
(2000) · Time to knit · doi:10.1016/s2211-0666(16)72573-4
Lei, Z., Lian-Fang, Y., & Morse, J. C. (2010) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.197116
Metadata
- Authors
- Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Vercellini, P.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-11
- Volume
- 26
- Issue
- 1
- Pages
- 3-13
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2117571760
- Semantic Scholar
- 63311710c2bb2995a9c0e275757690da0a84e5e1
- Cited by
- 180
- References
- 112
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 8 · 2018: 15 · 2017: 16 · 2016: 13 · 2015: 18 · 2014: 9 · 2013: 25 · 2012: 18
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Human Reproduction (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, progestins, oral contraceptives, hormonal manipulation, endometrioma recurrence, postoperative recurrence, endometriosis-associated ovarian cancer, deep infiltrating endometriosis, pelvic pain, drug safety and tolerability
- MeSH terms
- Contraceptives, Oral, Endometriosis, Female, Humans, Drugs, Investigational, Randomized Controlled Trials as Topic, Secondary Prevention, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
